PTCHD3 inhibitors belong to a class of chemical compounds that primarily target the PTCHD3 protein, or Patched domain-containing 3 protein. PTCHD3 is a membrane protein found in the human body, particularly in the brain, where it plays a critical role in regulating various cellular processes. These inhibitors are designed to modulate the activity of PTCHD3, typically by binding to the protein and altering its function. The inhibition of PTCHD3 can have significant implications for understanding cellular signaling pathways and potentially influencing specific biological processes.
The mechanism of action of PTCHD3 inhibitors usually involves interfering with the normal function of PTCHD3, which can be involved in the regulation of cell growth, differentiation, and various signaling pathways. By targeting PTCHD3, these inhibitors may disrupt its interactions with other proteins or molecules, ultimately affecting downstream cellular processes. Researchers are particularly interested in studying PTCHD3 inhibitors to unravel the intricate details of the signaling pathways in which this protein is involved. Understanding these pathways can provide insights into the fundamental biology of cells and may have implications for various fields, including neuroscience and cancer research, where PTCHD3 has been implicated in certain disease processes. Further research is necessary to elucidate the full scope of PTCHD3 inhibitor applications and their potential impact on our understanding of cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Inhibits Smoothened (SMO), potentially reducing PTCHD3-mediated signaling by downregulating the pathway. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Targets SMO, which may alter PTCHD3-related pathway activity via SMO inhibition. | ||||||
Erismodegib | 956697-53-3 | sc-396280 sc-396280A | 10 mg 100 mg | $255.00 $918.00 | ||
SMO antagonist, may indirectly decrease PTCHD3 activity by inhibiting downstream Hh signaling. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $63.00 $128.00 $200.00 | 6 | |
Gli antagonist, could indirectly reduce PTCHD3-related signaling by inhibiting Gli-mediated transcription. | ||||||
Jervine | 469-59-0 | sc-200934 sc-200934A | 1 mg 5 mg | $66.00 $240.00 | 1 | |
Inhibits SMO, potentially modulating PTCHD3 function by downregulating Hh pathway activity. | ||||||
Saridegib | 1037210-93-7 | sc-507351 | 5 mg | $3500.00 | ||
SMO inhibitor, may affect PTCHD3 by altering the Hh signaling cascade. | ||||||
Glasdegib | 1095173-27-5 | sc-507353 | 5 mg | $165.00 | ||
Inhibits SMO, potentially influencing PTCHD3 through changes in Hh pathway activity. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Though an antifungal, it has been shown to inhibit SMO, potentially affecting PTCHD3 function. | ||||||